Ana Martinez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3692130/publications.pdf

Version: 2024-02-01

316 papers	11,832 citations	26610 56 h-index	43868 91 g-index

342 all docs	342 docs citations	342 times ranked	12915 citing authors

#	Article	IF	Citations
1	First Non-ATP Competitive Glycogen Synthase Kinase 3 Î² (GSK-3Î²) Inhibitors:Â Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease. Journal of Medicinal Chemistry, 2002, 45, 1292-1299.	2.9	421
2	COVID-19: Drug Targets and Potential Treatments. Journal of Medicinal Chemistry, 2020, 63, 12359-12386.	2.9	348
3	Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Medicinal Research Reviews, 2002, 22, 373-384.	5.0	302
4	GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Frontiers in Molecular Neuroscience, 2011, 4, 32.	1.4	274
5	Novel Tacrineâ^'8-Hydroxyquinoline Hybrids as Multifunctional Agents for the Treatment of Alzheimerâ€™s Disease, with Neuroprotective, Cholinergic, Antioxidant, and Copper-Complexing Properties. Journal of Medicinal Chemistry, 2010, 53, 4927-4937.	2.9	253
6	New Tacrineâ€“4-Oxo-4H-chromene Hybrids as Multifunctional Agents for the Treatment of Alzheimerâ€™s Disease, with Cholinergic, Antioxidant, and Î²-Amyloid-Reducing Properties. Journal of Medicinal Chemistry, 2012, 55, 1303-1317.	2.9	244
7	Novel Tacrineâ^'Melatonin Hybrids as Dual-Acting Drugs for Alzheimer Disease, with Improved Acetylcholinesterase Inhibitory and Antioxidant Properties. Journal of Medicinal Chemistry, 2006, 49, 459-462.	2.9	240
8	Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors:â€‰ New Disease-Modifying Agents for Alzheimer's Disease. Journal of Medicinal Chemistry, 2005, 48, 7223-7233.	2.9	203
9	Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors. Current Pharmaceutical Design, 2006, 12, 4377-4387.	0.9	187
10	Regulation of Inflammatory Response in Neural Cells in Vitro by Thiadiazolidinones Derivatives through Peroxisome Proliferator-activated Receptor Î³ Activation. Journal of Biological Chemistry, 2005, 280, 21453-21462.	1.6	174
11	TNFÎ± disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice. Brain, Behavior, and Immunity, 2018, 69, 556-567.	2.0	161
12	Tacrineâ€“Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties. ChemMedChem, 2009, 4, 828-841.	1.6	154
13	Donepezilâ€“tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorganic and Medicinal Chemistry, 2005, 13, 6588-6597.	1.4	145
14	Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo. ACS Chemical Neuroscience, 2012, 3, 963-971.	1.7	139
15	Peripheral and Dual Binding Site Acetylcholinesterase Inhibitors: Implications in treatment of Alzheimers Disease. Mini-Reviews in Medicinal Chemistry, 2001, 1, 267-272.	1.1	134
16	Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. Brain, Behavior, and Immunity, 2016, 53, 207-222.	2.0	132
17	Manzamine B and E and Ircinal A Related Alkaloids from an IndonesianAcanthostrongylophoraSponge and Their Activity against Infectious, Tropical Parasitic, and Alzheimer's Diseases. Journal of Natural Products, 2006, 69, 1034-1040.	1.5	129
18	Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Medicinal Research Reviews, 2011, 31, 924-954.	5.0	124

#	Article	IF	Citations
19	Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structureâ€“Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimerâ€™s Disease. Journal of Natural Products, 2007, 70, 1397-1405.	1.5	123
20	GSK-3 Inhibitors: A Ray of Hope for the Treatment of Alzheimer's Disease?. Journal of Alzheimer's Disease, 2008, 15, 181-191.	1.2	119
21	Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1549-1556.	2.5	116
22	SAR and 3D-QSAR Studies on Thiadiazolidinone Derivatives:â€‰ Exploration of Structural Requirements for Glycogen Synthase Kinase 3 Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 7103-7112.	2.9	114
23	Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors. Medicinal Research Reviews, 2005, 25, 229-244.	5.0	111
24	NP031112, a Thiadiazolidinone Compound, Prevents Inflammation and Neurodegeneration under Excitotoxic Conditions: Potential Therapeutic Role in Brain Disorders. Journal of Neuroscience, 2007, 27, 5766-5776.	1.7	108
25	Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACEâ€1 and GSKâ€3Î² Inhibitors. Angewandte Chemie - International Edition, 2015, 54, 1578-1582.	7.2	107
26	Glycogen Synthase Kinase-3 Inhibitors Reverse Deficits in Long-term Potentiation and Cognition in Fragile X Mice. Biological Psychiatry, 2014, 75, 198-206.	0.7	101
27	Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3Î² Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 531-544.	2.9	100
28	Thienyl and Phenyl Î±-Halomethyl Ketones:â€‰ New Inhibitors of Glycogen Synthase Kinase (GSK-3Î²) from a Library of Compound Searching. Journal of Medicinal Chemistry, 2003, 46, 4631-4633.	2.9	98
29	Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2006, 15, 1-12.	1.9	97
30	Neuroprotective and Cholinergic Properties of Multifunctional Glutamic Acid Derivatives for the Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2009, 52, 7249-7257.	2.9	97
31	Protein Kinase CK-1 Inhibitors As New Potential Drugs for Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry, 2014, 57, 2755-2772.	2.9	95
32	Preclinical efficacy on GSKâ€3 inhibitors: Towards a future generation of powerful drugs. Medicinal Research Reviews, 2008, 28, 773-796.	5.0	93
33	Exploring the Binding Sites of Glycogen Synthase Kinase 3. Identification and Characterization of Allosteric Modulation Cavities. Journal of Medicinal Chemistry, 2011, 54, 8461-8470.	2.9	91
34	Reduction of body weight, liver steatosis and expression of stearoylâ€CoA desaturase 1 by the isoflavone daidzein in dietâ€induced obesity. British Journal of Pharmacology, 2011, 164, 1899-1915.	2.7	84
35	Switching Reversibility to Irreversibility in Glycogen Synthase Kinase 3 Inhibitors: Clues for Specific Design of New Compounds. Journal of Medicinal Chemistry, 2011, 54, 4042-4056.	2.9	84
36	Phosphodiesterase 7 Inhibition Preserves Dopaminergic Neurons in Cellular and Rodent Models of Parkinson Disease. PLoS ONE, 2011, 6, e17240.	1.1	83

#	Article	IF	Citations
37	New Melatoninâ€“N,N-Dibenzyl(N-methyl)amine Hybrids: Potent Neurogenic Agents with Antioxidant, Cholinergic, and Neuroprotective Properties as Innovative Drugs for Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2014, 57, 3773-3785.	2.9	81
38	Tau-Centric Multitarget Approach for Alzheimerâ€™s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3Î² and Tau-Aggregation Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 7640-7656.	2.9	81
39	N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. European Journal of Medicinal Chemistry, 2000, 35, 913-922.	2.6	78
40	Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2133-2145.	1.5	77
41	cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Expert Opinion on Therapeutic Patents, 2014, 24, 1311-1321.	2.4	77
42	Targeting autophagy in disease: established and new strategies. Autophagy, 2022, 18, 473-495.	4.3	77
43	5-Imino-1,2,4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3. Journal of Medicinal Chemistry, 2012, 55, 1645-1661.	2.9	76
44	Benzyl Derivatives of 2,1,3-Benzo- and Benzothieno[3,2-a]thiadiazine 2,2-Dioxides:â€‰ First Phosphodiesterase 7 Inhibitors. Journal of Medicinal Chemistry, 2000, 43, 683-689.	2.9	74
45	Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3. Journal of Immunology, 2013, 190, 5000-5011.	0.4	71
46	Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer's Disease Treatment. International Journal of Alzheimer's Disease, 2011, 2011, 1-7.	1.1	69
47	Glycogen Synthase Kinase-3 Inhibitors as Potent Therapeutic Agents for the Treatment of Parkinson Disease.. ACS Chemical Neuroscience, 2013, 4, 350-360.	1.7	69
48	Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice. Neuroscience, 2004, 128, 73-89.	1.1	68
49	GSK-3 Inhibitors: Discoveries and Developments. Current Medicinal Chemistry, 2004, 11, 755-763.	1.2	66
50	Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2012, 54, 750-763.	2.6	66
51	Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. European Journal of Medicinal Chemistry, 2012, 47, 175-185.	2.6	64
52	Amyloid Î²-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition. Alzheimer's Research and Therapy, 2018, 10, 24.	3.0	64
53	Î²-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): The first step towards an experimental model for sporadic ALS. Environmental Toxicology and Pharmacology, 2013, 36, 243-255.	2.0	60
54	PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury. PLoS ONE, 2011, 6, e15937.	1.1	59

#	Article	IF	Citations
55	Phosphodiesterase inhibitory properties of losartan. design and synthesis of new lead compounds. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 505-510.	1.0	58
56	Non-ATP competitive glycogen synthase kinase 3Î² (GSK-3Î²) inhibitors: Study of structural requirements for thiadiazolidinone derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 495-510.	1.4	57
57	Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin. European Journal of Medicinal Chemistry, 2013, 60, 479-489.	2.6	57
58	Tautomerism and acidity in 4-quinolone-3-carboxylic acid derivatives. Tetrahedron, 1992, 48, 6135-6150.	1.0	56
59	Synthesis, Structural Analysis, and Biological Evaluation of Thioxoquinazoline Derivatives as Phosphodiesteraseâ€...7 Inhibitors. ChemMedChem, 2009, 4, 866-876.	1.6	56
60	Dual inhibitor of PDE7 and GSK-3 â€“ VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology, 2013, 64, 205-214.	2.0	56
61	Targeting TDP-43 phosphorylation by Casein Kinase-1Î´ inhibitors: a novel strategy for the treatment of frontotemporal dementia. Molecular Neurodegeneration, 2016, 11, 36.	4.4	55
62	3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3Î² Fragment Hits against Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2015, 6, 1665-1682.	1.7	54
63	Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease: Synthesis, biological assessment, and molecular modeling. European Journal of Medicinal Chemistry, 2012, 57, 296-301.	2.6	53
64	Effect of Phosphodiesterase 7 (PDE7) Inhibitors in Experimental Autoimmune Encephalomyelitis Mice. Discovery of a New Chemically Diverse Family of Compounds. Journal of Medicinal Chemistry, 2012, 55, 3274-3284.	2.9	52
65	Subtly Modulating Glycogen Synthase Kinase 3 Î²: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. Journal of Medicinal Chemistry, 2017, 60, 4983-5001.	2.9	52
66	Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cellular and Molecular Life Sciences, 2013, 70, 3449-3462.	2.4	51
67	Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs?. Expert Opinion on Therapeutic Patents, 2002, 12, 1527-1536.	2.4	49
68	Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorganic and Medicinal Chemistry, 2009, 17, 6914-6925.	1.4	49
69	Synthesis, Pharmacological Assessment, and Molecular Modeling of Acetylcholinesterase/Butyrylcholinesterase Inhibitors: Effect against Amyloid-Î²-Induced Neurotoxicity. ACS Chemical Neuroscience, 2013, 4, 547-565.	1.7	49
70	CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-a]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. European Journal of Medicinal Chemistry, 2001, 36, 333-338.	2.6	48
71	A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimerâ€™s and Prion Diseases. ACS Medicinal Chemistry Letters, 2013, 4, 225-229.	1.3	48
72	Comparative assessment of <scp>PDE</scp> 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis. British Journal of Pharmacology, 2013, 170, 602-613.	2.7	48

#	Article	IF	Citations
73	Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors. Molecules, 2016, 21, 193.	1.7	48
74	Design and synthesis of N-benzylpiperidineâ€“purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. Bioorganic and Medicinal Chemistry, 2005, 13, 6795-6802.	1.4	46
75	Old phenothiazine and dibenzothiadiazepine derivatives for tomorrowâ€™s neuroprotective therapies against neurodegenerative diseases. European Journal of Medicinal Chemistry, 2010, 45, 6152-6158.	2.6	46
76	N-Acylaminophenothiazines: Neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimerâ€™s disease. European Journal of Medicinal Chemistry, 2011, 46, 2224-2235.	2.6	46
77	New cinnamic â€“ N-benzylpiperidine and cinnamic â€“ N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties. European Journal of Medicinal Chemistry, 2016, 121, 376-386.	2.6	46
78	From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 139, 773-791.	2.6	46
79	Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1Î´ kinase inhibitor treatment. Scientific Reports, 2020, 10, 4449.	1.6	44
80	Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. European Journal of Medicinal Chemistry, 2014, 73, 56-72.	2.6	43
81	PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opinion on Therapeutic Patents, 2008, 18, 1127-1139.	2.4	42
82	Potent Î²-Amyloid Modulators. Neurodegenerative Diseases, 2008, 5, 153-156.	0.8	42
83	Tideglusib, a chemical inhibitor of GSK3Î², attenuates hypoxic-ischemic brain injury in neonatal mice. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 2076-2085.	1.1	40
84	Interference of the complex between NCS-1 and Ric8a with phenothiazines regulates synaptic function and is an approach for fragile X syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E999-E1008.	3.3	40
85	Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Scientific Reports, 2017, 7, 43545.	1.6	40
86	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). Expert Opinion on Therapeutic Patents, 2017, 27, 657-666.	2.4	40
87	Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimerâ€™s disease and other neurodegenerative disorders. Expert Opinion on Therapeutic Patents, 2000, 10, 1519-1527.	2.4	39
88	Polyaniline-based microelectrodes for sensing ascorbic acid in beverages. Current Applied Physics, 2008, 8, 320-323.	1.1	38
89	Phosphodiesterase 7 Inhibition Induces Dopaminergic Neurogenesis in Hemiparkinsonian Rats. Stem Cells Translational Medicine, 2015, 4, 564-575.	1.6	38
90	Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease. European Journal of Medicinal Chemistry, 2018, 156, 534-553.	2.6	38

#	Article	IF	Citations
91	TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis. ACS Chemical Neuroscience, 2019, 10, 1183-1196.	1.7	37
92	Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo. Stem Cells, 2017, 35, 458-472.	1.4	36
93	Synthesis and Potential Muscarinic Receptor Binding and Antioxidant Properties of 3-(Thiadiazolyl)pyridine 1-Oxide Compounds. Archiv Der Pharmazie, 1999, 332, 191-194.	2.1	35
94	CODES/Neural Network Model: a Useful Tool for in Silico Prediction of Oral Absorption and Blood-Brain Barrier Permeability of Structurally Diverse Drugs. QSAR and Combinatorial Science, 2004, 23, 89-98.	1.5	34
95	Glycogen Synthase Kinase 3: A Target for Novel Mood Disorder Treatments. , 0, , 125-154.		34
96	Non-Cholinergic Pharmacotherapy Approaches to the Future Treatment of Alzheimers Disease. Mini-Reviews in Medicinal Chemistry, 2002, 2, 37-50.	1.1	33
97	CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. European Journal of Medicinal Chemistry, 2008, 43, 1349-1359.	2.6	33
98	Application of BACE1 immobilized enzyme reactor for the characterization of multifunctional alkaloids from Corydalis cava (Fumariaceae) as Alzheimer's disease targets. FÃ¬toterapÃ¬Ã¢, 2016, 109, 241-247.	1.1	33
99	<scp>GSK</scp>â€3Î² inhibitor <scp>TDZD</scp>â€8 reduces neonatal hypoxicâ€ischemic brain injury in mice. CNS Neuroscience and Therapeutics, 2017, 23, 405-415.	1.9	33
100	Identification of new allosteric sites and modulators of AChE through computational and experimental tools. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1034-1047.	2.5	33
101	Development of Bloodâ€“Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. Journal of Medicinal Chemistry, 2016, 59, 7584-7597.	2.9	32
102	Dual Binding Site Acetylcholinesterase Inhibitors: Potential New Disease-Modifying Agents for AD. Journal of Molecular Neuroscience, 2006, 30, 85-88.	1.1	31
103	Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer’s Disease. Current Topics in Medicinal Chemistry, 2013, 13, 1808-1819.	1.0	31
104	The problem of the existence of C(Ar)â€“H â‹¯ N intramolecular hydrogen bonds in a family of 9-azaphenyl-9H-carbazoles. Journal of the Chemical Society Perkin Transactions II, 1993, , 1547-1555.	0.9	30
105	Marine compounds for the therapeutic treatment of neurological disorders. Expert Opinion on Therapeutic Patents, 2005, 15, 1377-1386.	2.4	30
106	5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3Î² (GSK-3Î²) and phosphodiesterase 7 (PDE7) inhibitors: Determination of bloodâ€“brain barrier penetration and binding to human serum albumin. European Journal of Pharmaceutical Sciences, 2012, 45, 677-684.	1.9	30
107	Synthesis, pharmacological assessment, and molecular modeling ofÂ6-chloro-pyridonepezils: New dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2013, 67, 64-74.	2.6	30
108	<scp>PDE</scp>7 inhibitor <scp>TC</scp>3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. British Journal of Pharmacology, 2015, 172, 4277-4290.	2.7	30

#	Article	IF	Citations
109	Kinase Inhibitors as Underexplored Antiviral Agents. Journal of Medicinal Chemistry, 2022, 65, 935-954.	2.9	30
110	Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. Neurobiology of Aging, 2015, 36, 1160-1173.	1.5	29
111	Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2019, 27, 931-943.	1.4	29
112	Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. European Journal of Medicinal Chemistry, 2019, 161, 39-47.	2.6	29
113	The Potential Role of Glycogen Synthase Kinase 3 Inhibitors as Amyotrophic Lateral Sclerosis Pharmacological Therapy. Current Medicinal Chemistry, 2011, 18, 3028-3034.	1.2	28
114	Medicinal and Biological Chemistry (MBC) Library: An Efficient Source of New Hits. Journal of Chemical Information and Modeling, 2017, 57, 2143-2151.	2.5	28
115	Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa. Molecular Neurodegeneration, 2018, 13, 19.	4.4	28
116	Novel Curcumin-Diethyl Fumarate Hybrid as a Dualistic GSK-3Î² Inhibitor/Nrf2 Inducer for the Treatment of Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2020, 11, 2728-2740.	1.7	28
117	Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. British Journal of Pharmacology, 2021, 178, 1316-1335.	2.7	28
118	Benzothiadiazine Dioxide Dibenzyl Derivatives as Potent Human Cytomegalovirus Inhibitors:â€‰ Synthesis and Comparative Molecular Field Analysis. Journal of Medicinal Chemistry, 2000, 43, 3218-3225.	2.9	27
119	Nonnucleoside Human Cytomegalovirus Inhibitors:â€‰ Synthesis and Antiviral Evaluation of (Chlorophenylmethyl)benzothiadiazine Dioxide Derivatives. Journal of Medicinal Chemistry, 2000, 43, 3267-3273.	2.9	27
120	Recent strategies in the development of new human cytomegalovirus inhibitors. Medicinal Research Reviews, 2001, 21, 227-244.	5.0	27
121	O-Pyrazolylpropynyl-Hydroxylamines as Versatile Intermediates in the Synthesis of Compounds of Pharmacological Interest. Synthesis, 2001, 2001, 1711-1715.	1.2	27
122	Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: Implication of ERK1/2 and PPARÎ³ receptors. Experimental Neurology, 2008, 212, 93-99.	2.0	27
123	A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 2012, 48, 206-213.	2.6	27
124	New flavonoid â€“ N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for AlzheimerÂ´s disease endowed with neurogenic properties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 712-727.	2.5	27
125	A ¹H and ¹³c Nmr study of the structure and tautomerism of 4â€pyrazolylpyrazolinones. Journal of Heterocyclic Chemistry, 1990, 27, 865-870.	1.4	26
126	Novel Potential Agents for Human Cytomegalovirus Infection:â€‰ Synthesis and Antiviral Activity Evaluation of Benzothiadiazine Dioxide Acyclonucleosides. Journal of Medicinal Chemistry, 1999, 42, 1145-1150.	2.9	26

#	Article	IF	Citations
127	Benzothiazepine CGP37157 and Its Isosteric 2â€²-Methyl Analogue Provide Neuroprotection and Block Cell Calcium Entry. ACS Chemical Neuroscience, 2012, 3, 519-529.	1.7	26
128	1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 665-670.	2.5	26
129	Correction of Glycogen Synthase Kinase 3Î² in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice. Molecular and Cellular Biology, 2019, 39, .	1.1	26
130	Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. European Journal of Medicinal Chemistry, 2021, 210, 112968.	2.6	26
131	Crosstalk between Phosphodiesterase 7 and Glycogen Synthase Kinase-3: Two Relevant Therapeutic Targets for Neurological Disorders. ACS Chemical Neuroscience, 2014, 5, 194-204.	1.7	25
132	Mitophagy Modulation, a New Player in the Race against ALS. International Journal of Molecular Sciences, 2021, 22, 740.	1.8	25
133	Is drug repurposing really the future of drug discovery or is new innovation truly the way forward?. Expert Opinion on Drug Discovery, 2021, 16, 1-3.	2.5	25
134	The first enantioselective synthesis of palinurin. Chemical Communications, 2009, , 3252.	2.2	24
135	Identification in Silico and Experimental Validation of Novel Phosphodiesterase 7 Inhibitors with Efficacy in Experimental Autoimmune Encephalomyelitis Mice. ACS Chemical Neuroscience, 2012, 3, 793-803.	1.7	24
136	Modulation of cAMP-Specific PDE without Emetogenic Activity: New Sulfide-Like PDE7 Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 8590-8607.	2.9	24
137	Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. European Journal of Medicinal Chemistry, 2017, 138, 328-342.	2.6	24
138	Potential anti-Alzheimer effects of selected Lamiaceae plants through polypharmacology on glycogen synthase kinase-3Î², Î²-secretase, and casein kinase 1Î´. Industrial Crops and Products, 2019, 138, 111431.	2.5	24
139	Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3Î² as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2021, 22, 8975.	1.8	24
140	Neurogenic Potential Assessment and Pharmacological Characterization of 6-Methoxy-1,2,3,4-tetrahydro-Î²-carboline (Pinoline) and Melatoninâ€“Pinoline Hybrids. ACS Chemical Neuroscience, 2015, 6, 800-810.	1.7	23
141	New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with Ïƒ-1 agonism and Î²-secretase inhibition. Future Medicinal Chemistry, 2016, 8, 1191-1207.	1.1	23
142	A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. Journal of Chemical Neuroanatomy, 2017, 80, 27-36.	1.0	23
143	The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. Neuropharmacology, 2017, 116, 174-187.	2.0	23
144	Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients. Molecular Neurobiology, 2019, 56, 2424-2432.	1.9	23

#	Article	IF	Citations
145	Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinsonâ€™s Disease?. Current Medicinal Chemistry, 2014, 21, 1171-1187.	1.2	23
146	An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: The case of a palinurin-related data set of non-ATP competitive Glycogen Synthase Kinase 3Î² (GSK-3Î²) inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 860-869.	2.6	22
147	Morphometric and neurochemical alterations found in l-BMAA treated rats. Environmental Toxicology and Pharmacology, 2015, 39, 1232-1245.	2.0	22
148	Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs, 2017, 26, 403-414.	1.9	22
149	A Triazolotriazineâ€Based Dual GSKâ€3Î²/CKâ€1Î´ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition. ChemMedChem, 2019, 14, 310-314.	1.6	22
150	Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice. JCI Insight, 2017, 2, e91782.	2.3	22
151	Analysis of Î²-N-methylamino- l -alanine (L-BMAA) neurotoxicity in rat cerebellum. NeuroToxicology, 2015, 48, 192-205.	1.4	21
152	Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. European Journal of Medicinal Chemistry, 2017, 130, 60-72.	2.6	21
153	Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods. Pharmaceuticals, 2021, 14, 332.	1.7	21
154	From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2015, 22, 3789-3806.	1.2	21
155	Reaction of 4â€hydrazinoquinolines with Î²â€diketones. Synthesis and spectroscopy (¹h,) Tj ETQq1 1 0.784314 rgBT /O 733-738.	1.4	20
156	Selective dopamine receptors: Synthesis, complexing properties, and molecular modelling studies of new podands derived from 4-hydroxy-1H-pyrazole. Tetrahedron, 1999, 55, 2763-2772.	1.0	20
157	Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase. Bioorganic and Medicinal Chemistry, 2008, 16, 6193-6206.	1.4	20
158	Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDPâ€43â€related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Journal of Neurochemistry, 2021, 156, 379-390.	2.1	20
159	TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. Journal of Medicinal Chemistry, 2022, 65, 1585-1607.	2.9	20
160	On the Tautomerism of 2â€Phenacylâ€4â€pyrimidinones and Related Compounds. Chemische Berichte, 1989, 122, 919-924.	0.2	19
161	Synthesis of Î³[CH(CN)NH] pseudopeptides. A new peptide bond surrogate. Tetrahedron Letters, 1991, 32, 7579-7582.	0.7	19
162	Arylimino-1,2,4-thiadiazolidinones: A new family of potassium channel openers. Bioorganic and Medicinal Chemistry, 1997, 5, 1275-1283.	1.4	19

#	Article	IF	Citations
163	Biology-oriented development of novel lipophilic antioxidants with neuroprotective activity. RSC Advances, 2015, 5, 15800-15811.	1.7	19
164	Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 522-526.	2.5	19
165	Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target. Antiviral Research, 2021, 194, 105167.	1.9	19
166	The structure of the compounds resulting from the reaction of arylhydrazines with dehydroacetic acid: an NMR and crystallographic study. Tetrahedron, 1995, 51, 4891-4906.	1.0	18
167	Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. European Journal of Medicinal Chemistry, 2018, 145, 431-444.	2.6	18
168	A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential. ACS Chemical Neuroscience, 2019, 10, 279-294.	1.7	18
169	Synthesis and spectroscopic properties of Nâ€azolylpropanamides. Journal of Heterocyclic Chemistry, 1988, 25, 225-229.	1.4	17
170	Application of ultrasonic nebulization for the determination of rare earth elements in phosphates and related sedimentary rocks using inductively coupled plasma atomic emission spectrometry with comments on dissolution procedures. Journal of Analytical Atomic Spectrometry, 1993, 8, 833.	1.6	17
171	Semiempirical (AM1, PM3 and SAM1) calculations of the protonation enthalpies of proton sponges related to 1,8-diaminonaphthalene. Estimation of the aqueous basicity of new designed superbases. Journal of the Chemical Society Perkin Transactions II, 1995, , 923-927.	0.9	17
172	Regioselective lipase-catalyzed synthesis of l-glutamic Î±-monoamide derivatives. Effect of the N-blocking group. Tetrahedron, 1997, 53, 11745-11752.	1.0	17
173	Synthesis and Biological Evaluation of Tacrine-Thiadiazolidinone Hybrids as Dual Acetylcholinesterase Inhibitors. Archiv Der Pharmazie, 2005, 338, 18-23.	2.1	17
174	Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	17
175	Multitarget Cannabinoids as Novel Strategy for Alzheimer Disease. Current Alzheimer Research, 2013, 10, 229-239.	0.7	17
176	New 1,2,6-thiadiazine dioxide acyclonucleosides: Synthesis and antiviral evaluation. Bioorganic and Medicinal Chemistry, 1995, 3, 1527-1535.	1.4	16
177	Imidazothiadiazine dioxides: synthesis and antiviral activity. Bioorganic and Medicinal Chemistry, 1999, 7, 1617-1623.	1.4	16
178	Insights into real-time chemical processes in a calcium sensor protein-directed dynamic library. Nature Communications, 2019, 10, 2798.	5.8	16
179	Indazolylketones as new multitarget cannabinoid drugs. European Journal of Medicinal Chemistry, 2019, 166, 90-107.	2.6	16
180	Molecular Alterations in Sporadic and SOD1-ALS Immortalized Lymphocytes: Towards a Personalized Therapy. International Journal of Molecular Sciences, 2021, 22, 3007.	1.8	16

#	Article	IF	Citations
181	Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders. Current Topics in Medicinal Chemistry, 2016, 16, 3527-3535.	1.0	16
182	Synthesis and biological evaluation of 4-quinolone ribosides. Journal of the Chemical Society Perkin Transactions 1, 1993, , 845.	0.9	15
183	Resolution of 1-(4-amino-3-chloro-5-cyanophenyl)-2-bromo-1-ethanol by lipase mediated enantioselective alcoholysis, hydrolysis and acylation. Tetrahedron: Asymmetry, 1998, 9, 2229-2232.	1.8	15
184	Prediction of Drug Half-life Values of Antihistamines Based on the CODES/Neural Network Model. QSAR and Combinatorial Science, 2000, 19, 448-454.	1.4	15
185	Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease modifying agents. Expert Opinion on Therapeutic Patents, 2003, 13, 1725-1732.	2.4	15
186	Anticonvulsant and neuroprotective effects of the novel calcium antagonist NP04634 on kainic acidâ€induced seizures in rats. Journal of Neuroscience Research, 2009, 87, 3687-3696.	1.3	15
187	The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury. Journal of Neurochemistry, 2012, 122, 1193-1202.	2.1	15
188	Dibenzo[1,4,5]thiadiazepine: A hardly-known heterocyclic system with neuroprotective properties of potential usefulness in the treatment of neurodegenerative diseases. European Journal of Medicinal Chemistry, 2014, 81, 350-358.	2.6	15
189	Impairments in cognition and neural precursor cell proliferation in mice expressing constitutively active glycogen synthase kinase-3. Frontiers in Behavioral Neuroscience, 2015, 9, 55.	1.0	15
190	Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. European Journal of Medicinal Chemistry, 2020, 190, 112090.	2.6	15
191	Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. Antiviral Research, 2021, 186, 105011.	1.9	15
192	Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles. International Journal of Molecular Sciences, 2021, 22, 3206.	1.8	15
193	CB1 Blockade Potentiates Down-Regulation of Lipogenic Gene Expression in Perirenal Adipose Tissue in High Carbohydrate Diet-Induced Obesity. PLoS ONE, 2014, 9, e90016.	1.1	15
194	Lipase-Mediated Acylation of Acyclonucleosides. Application to Novel Fluoroquinolone Derivatives. Synthetic Communications, 1991, 21, 1477-1480.	1.1	14
195	SO2 extrusion in 1,2,6-thiadiazine 1,1-dioxides: a novel synthesis of pyrazoles. Canadian Journal of Chemistry, 1993, 71, 410-412.	0.6	14
196	Dioxides of bicyclic thiadiazines: a new family of smooth muscle relaxants. Bioorganic and Medicinal Chemistry, 1995, 3, 179-185.	1.4	14
197	Benzothiadiazine dioxide acyclonucleosides as lead compounds for the development of new agents against human cytomegalovirus and varicella-zoster virus infections. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1031-1032.	1.0	14
198	Serum- and glucocorticoid-induced kinase 1, a new therapeutic target for autophagy modulation in chronic diseases. Expert Opinion on Therapeutic Targets, 2020, 24, 231-243.	1.5	14

#	Article	IF	Citations
199	Synthesis and NMR spectroscopy (¹H ¹³C) of 1â€(2â€²â€benzothiazolyl)â€3(5),4â€polymethylenepyrazoles and related compounds. Journal of Heterocyclic Chemistry, 1991, 28, 647-651.	1.4	13
200	Regioselective lipase-mediated acylation-deacylation in thiadiazine diacyclonucleosides.. Tetrahedron, 1994, 50, 13865-13870.	1.0	13
201	Tautomerism of benzo- and cyclopenta-[1,2,6]thiadiazine S,S-dioxides. Journal of the Chemical Society Perkin Transactions II, 1994, , 1561-1564.	0.9	13
202	Candida antarctica lipase B catalysed amidation of pyroglutamic acid derivatives. A reaction survey. Journal of Molecular Catalysis B: Enzymatic, 1999, 7, 299-306.	1.8	13
203	Inhibition of hippocampal long-term potentiation by high-fat diets. NeuroReport, 2017, 28, 354-359.	0.6	13
204	Structure of 1,2,6-thiadiazine 1,1-dioxides. Journal of Physical Organic Chemistry, 1990, 3, 470-476.	0.9	12
205	Applications of a statistical model to the analysis of the kinetic parameters in isothermal and non-isothermal crystallization of polymer blends based on PVDF. Polymer, 1997, 38, 2741-2746.	1.8	12
206	On the tautomerism of 2,1,3-benzothiadiazinone S,S-dioxide and related compounds. Tetrahedron, 1999, 55, 12405-12410.	1.0	12
207	Intramolecular oxidative cyclizations in heteroarylthioureas: A versatile pathway to bridgehead heterocyclic systems. Journal of Heterocyclic Chemistry, 1999, 36, 991-995.	1.4	12
208	Synthesis of NewN-(4-Pyridyl)-1-aminopyrazoles and Their Muscarinic and Adrenergic Properties. Archiv Der Pharmazie, 2000, 333, 118-122.	2.1	12
209	Hindered Inversion/Rotation in Diheteroaryl Alkyl Amines with a N-(1-Pyrazolyl) Group: Dynamic NMR and Molecular Modelling Studies. Tetrahedron, 2000, 56, 1739-1743.	1.0	12
210	Synthesis and muscarinic activities of O-[(Benzyl- or benzoyl-pyrazolyl)propynyl]-oximes of N-methylpiperidinone, 3-tropinone, and 3-quinuclidinone. Bioorganic and Medicinal Chemistry, 2003, 11, 2263-2268.	1.4	12
211	NP04634 prevents cell damage caused by calcium overload and mitochondrial disruption in bovine chromaffin cells. European Journal of Pharmacology, 2009, 607, 47-53.	1.7	12
212	Highâ€fructose corn syrup consumption in adolescent rats causes bipolarâ€like behavioural phenotype with hyperexcitability in hippocampal CA3â€CA1 synapses. British Journal of Pharmacology, 2018, 175, 4450-4463.	2.7	12
213	Towards discovery of new leishmanicidal scaffolds able to inhibit Leishmania GSK-3. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 199-210.	2.5	12
214	Synthesis and intramolecular cyclization of bisthiadiazinylmethane derivatives. Tetrahedron, 1985, 41, 3105-3116.	1.0	11
215	Lipase-catalysed synthesis of new acetylcholinesterase inhibitors: N -benzylpiperidine aminoacid derivatives. Bioorganic and Medicinal Chemistry, 2000, 8, 731-738.	1.4	11
216	Benzothiadiazine Dioxide Human Cytomegalovirus Inhibitors: Synthesis and Antiviral Evaluation of Main Heterocycle Modified Derivatives. Antiviral Chemistry and Chemotherapy, 2003, 14, 107-114.	0.3	11

#	Article	IF	Citations
217	Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinsonâ€™s disease. Future Medicinal Chemistry, 2017, 9, 731-748.	1.1	11
218	QSAR Modelling to Identify LRRK2 Inhibitors for Parkinsonâ€™s Disease. Journal of Integrative Bioinformatics, 2019, 16, .	1.0	11
219	GSK3 Inhibitor-Induced Dentinogenesis Using a Hydrogel. Journal of Dental Research, 2022, 101, 46-53.	2.5	11
220	Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry, 2022, 65, 1867-1882.	2.9	11
221	Synthesis of 2S-Dioxo Isosteres of Purine and Pyrimidine Nucleosides IV. Selective Glycosylation of 4-Amino-5H-Imidazo [4, 5-c]-1, 2, 6-Thiadiazine 2, 2-Dioxide. Nucleosides, Nucleotides and Nucleic Acids, 1987, 6, 631-642.	0.4	10
222	Chlorophenylmethyl benzothiadiazine dioxides derivatives: Potent human cytomegalovirus inhibitors. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3133-3136.	1.0	10
223	Editorial [Hot Topic:Advances in Alzheimer Therapy: Understanding Pharmacological Approaches to the Disease (Guest Editors: Ana Martinez, Debomoy K. Lahiri, Ezio Giacobini and Nigel H. Greig)]. Current Alzheimer Research, 2009, 6, 83-85.	0.7	10
224	Adiponectin promoter activator NP-1 reduces body weight and hepatic steatosis in high-fat diet-fed animals. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E817-E830.	1.8	10
225	Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. PLoS ONE, 2016, 11, e0162723.	1.1	10
226	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth. European Journal of Medicinal Chemistry, 2016, 116, 281-289.	2.6	10
227	Biological and Pharmacological Characterization of Benzothiazole-Based CK-1Î´ Inhibitors in Models of Parkinsonâ€™s Disease. ACS Omega, 2017, 2, 5215-5220.	1.6	10
228	Deciphering the Inhibition of the Neuronal Calcium Sensor 1 and the Guanine Exchange Factor Ric8a with a Small Phenothiazine Molecule for the Rational Generation of Therapeutic Synapse Function Regulators. Journal of Medicinal Chemistry, 2018, 61, 5910-5921.	2.9	10
229	Computer-aided molecular design of pyrazolotriazines targeting glycogen synthase kinase 3. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 87-96.	2.5	10
230	From simple quinoxalines to potent oxazolo[5,4-f]quinoxaline inhibitors of glycogen-synthase kinase 3 (GSK3). Organic and Biomolecular Chemistry, 2020, 18, 154-162.	1.5	10
231	Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate. Journal of Medicinal Chemistry, 2020, 63, 2638-2655.	2.9	10
232	Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles. Pharmaceutics, 2021, 13, 180.	2.0	10
233	New Synthetic Route to of 1,2,4-Thiadiazolines and 1,3-Thiazolines via Thiadiazolopyridinium Salts. Heterocycles, 1996, 43, 2657.	0.4	10
234	Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades. Journal of Medicinal Chemistry, 2022, 65, 4727-4751.	2.9	10

#	Article	IF	Citations
235	Rotational isomerism in 6-Î²-D-glucopyranosides of methyl-1,2,6-thiadiazin-3(2H)-one 1,1-dioxides. Journal of the Chemical Society Perkin Transactions II, 1990, , 783-786.	0.9	9
236	Regioselective Mucor miehei lipase catalyzed synthesis of podands containing a 1,3-bis(1H-Pyrazol-1-yl)propane unit. Tetrahedron, 1995, 51, 2417-2426.	1.0	9
237	The Regio- and Stereocontrolled Ring Opening of Heteroarylglycidates with Nitrogen Nucleophiles. Tetrahedron Letters, 1995, 36, 5417-5420.	0.7	9
238	Synthesis and Antiviral Activity of Modified 1,2,6-Thiadiazine Dioxide Acyclonucleosides. Nucleosides & Nucleotides, 1997, 16, 265-276.	0.5	9
239	Regioselective lipase-catalysed Î³-monoamidation of d-glutamic acid diesters: effect of the N-protecting group. Tetrahedron: Asymmetry, 2000, 11, 2537-2545.	1.8	9
240	Glycogen Synthase Kinase-3. International Journal of Alzheimer's Disease, 2011, 2011, 1-1.	1.1	9
241	1-Aryl-3-(4-methoxybenzyl)ureas as potentially irreversible glycogen synthase kinase 3 inhibitors: Synthesis and biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1597-1600.	1.0	9
242	Functionalized aromatic esters of the Amaryllidaceae alkaloid haemanthamine and their in vitro and in silico biological activity connected to Alzheimerâ€™s disease. Bioorganic Chemistry, 2020, 100, 103928.	2.0	9
243	Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase-3Î². Journal of Medicinal Chemistry, 2021, 64, 1497-1509.	2.9	9
244	Developing novel classes of protein kinase CK1Î´ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems. European Journal of Medicinal Chemistry, 2021, 216, 113331.	2.6	9
245	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Proteinâ€Templated Synthesis. Angewandte Chemie - International Edition, 2021, 60, 19344-19354.	7.2	9
246	Selective carriers of norepinephrine and ammonium ions: Ionophoric properties and molecular modelling studies of diester crown compounds containing a 1,3-bis(1H-pyrazol-1-yl)propane unit. Bioorganic and Medicinal Chemistry, 1997, 5, 363-367.	1.4	8
247	Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis. Future Medicinal Chemistry, 2019, 11, 1703-1720.	1.1	8
248	In vitro biological activity of Salvia fruticosa Mill. infusion against amyloid Î²-peptide-induced toxicity and inhibition of GSK-3Î², CK-1Î´, and BACE-1 enzymes relevant to Alzheimer's disease. Saudi Pharmaceutical Journal, 2021, 29, 236-243.	1.2	8
249	Synthesis and Cytostatic Screening of an SO2 Analogue of Doridosine. Archiv Der Pharmazie, 1988, 321, 99-101.	2.1	7
250	Novel agents for the treatment of human cytomegalovirus infection. Expert Opinion on Therapeutic Patents, 2000, 10, 165-177.	2.4	7
251	The adiponectin promoter activator NP-1 induces high levels of circulating TNFÎ± and weight loss in obese (fa/fa) Zucker rats. Scientific Reports, 2018, 8, 9858.	1.6	7
252	Theoretical and Experimental Approaches Aimed at Drug Design Targeting Neurodegenerative Diseases. Processes, 2019, 7, 940.	1.3	7

#	Article	IF	Citations
253	Phenotypic Assay Leads to Discovery of Mitophagy Inducers with Therapeutic Potential for Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2021, 12, 4512-4523.	1.7	7
254	Conformation and ortho steric effects in a series of 2â€(pyrazolâ€1â€yl)quinolines. Journal of Heterocyclic Chemistry, 1996, 33, 323-326.	1.4	6
255	Regioselective lipase catalyzed synthesis of diester crowns. New asymmetric macrocycles containing a 1,3-bis(1H-pyrazol-1-yl)propane unit. Tetrahedron, 1997, 53, 11481-11488.	1.0	6
256	Regioselective Lipase-Catalysed Amidation of DicarboxylicN-Blocked Amino Acid Diesters â€“ Effect of the Side-Chain Length. European Journal of Organic Chemistry, 1999, 1999, 2835-2839.	1.2	6
257	Anti-HIV-1 Activity of Benzothiadiazine Dioxide. Antiviral Chemistry and Chemotherapy, 2001, 12, 347-351.	0.3	6
258	Good oral absorption prediction on non-nucleoside benzothiadiazine dioxide human cytomegalovirus inhibitors using combined chromatographic and neuronal network techniques. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1919-1921.	1.0	6
259	Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects. Molecules, 2017, 22, 1472.	1.7	6
260	Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model. Neurobiology of Aging, 2020, 96, 148-154.	1.5	6
261	Glycogen Synthase Kinase-3 Maleimide Inhibitors As Potential PET-Tracers for Imaging Alzheimerâ€™s Disease: ¹¹C-Synthesis and In Vivo Proof of Concept. Journal of Medicinal Chemistry, 2022, 65, 1342-1351.	2.9	6
262	GSK-3 Inhibitors: From theÂBrain to theÂRetina and Back Again. Advances in Experimental Medicine and Biology, 2019, 1185, 437-441.	0.8	6
263	Thiadiazolopyridinium Salts: Intermediates for Heterocyclic Synthesis. Heterocycles, 1994, 38, 1737.	0.4	6
264	(E)-1-alkyl-[2-(1H-azol-2-yl)vinyl]pyridinium salts: theoretical analysis, synthesis and evaluation of their interaction with choline acetyltransferase.. Bioorganic and Medicinal Chemistry Letters, 1992, 2, 1493-1496.	1.0	5
265	Title is missing!. Biotechnology Letters, 1998, 20, 261-263.	1.1	5
266	Synthesis of nonsymmetrically 3,4â€disubstituted 1,2,5â€thiadiazole dioxides. Journal of Heterocyclic Chemistry, 1998, 35, 297-300.	1.4	5
267	Benzothiadiazine dioxides (BTD) derivatives as non-nucleoside human cytomegalovirus (HCMV) inhibitors. study of structural requirements for biological activityâ˜†. Bioorganic and Medicinal Chemistry, 2003, 11, 2395-2402.	1.4	5
268	Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities. European Journal of Medicinal Chemistry, 2013, 70, 781-788.	2.6	5
269	Allosteric Modulation of GSK-3Î² as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related. International Journal of Molecular Sciences, 2021, 22, 7367.	1.8	5
270	Phosphodiesterase Inhibitors as a New Therapeutic Approach for the Treatment of Parkinsonâ€™s Disease. RSC Drug Discovery Series, 2013, , 294-307.	0.2	5

#	Article	IF	Citations
271	Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease-modifying agents. Expert Opinion on Therapeutic Patents, 2003, 13, 1725-1732.	2.4	5
272	N-Glucosyl-5-amino-4-carbamoyl- and 4-Ethoxycarbonylimidazoles as Potential Precursors of 4-Oxoimdazo[4,5-c]-1,2,6-thiadiazine 2,2-Dioxides. Heterocycles, 1986, 24, 3451.	0.4	5
273	Glycosylation of Epigallocatechin Gallate by Engineered Glycoside Hydrolases from Talaromyces amestolkiae: Potential Antiproliferative and Neuroprotective Effect of These Molecules. Antioxidants, 2022, 11, 1325.	2.2	5
274	Base promoted transformation on thiadiazolopyridinium chlorides. Journal of Heterocyclic Chemistry, 1997, 34, 337-340.	1.4	4
275	Thienothiadiazine 2,2-Dioxide Acyclonucleosides: Synthesis and Antiviral Activity. Antiviral Chemistry and Chemotherapy, 2000, 11, 221-230.	0.3	4
276	AMPA Glutamate Receptors and Neuropathic Pain. Mini-Reviews in Medicinal Chemistry, 2003, 3, 757-763.	1.1	4
277	3-Amino Pyrazoles as Potent and Selective Glycogen Kinase Synthase 3 (GSK-3) Inhibitors. , 0, , 281-305.		4
278	Marine Compounds as a New Source for Glycogen Synthase Kinase 3 Inhibitors. , 0, , 307-331.		4
279	3-(Benzyloxy)-1-(5-[¹⁸F]fluoropentyl)-5-nitro-1H-indazole: a PET radiotracer to measure acetylcholinesterase in brain. Future Medicinal Chemistry, 2017, 9, 983-994.	1.1	4
280	Driving next-generation autophagy researchers towards translation (DRIVE), an international PhD training program on autophagy. Autophagy, 2019, 15, 347-351.	4.3	4
281	Dynamics of Central Remyelination and Treatment Evolution in a Model of Multiple Sclerosis with Optic Coherence Tomography. International Journal of Molecular Sciences, 2021, 22, 2440.	1.8	4
282	Small molecule inhibitors of mammalian GSK-3Î² promote in vitro plant cell reprogramming and somatic embryogenesis in crop and forest species. Journal of Experimental Botany, 2021, 72, 7808-7825.	2.4	4
283	The regio- and stereocontrolled ring opening of heteroarylglycidates with nitrogen nucleophiles. Tetrahedron Letters, 1995, 36, 5417-5420.	0.7	4
284	Naphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3. Biomedicines, 2022, 10, 1136.	1.4	4
285	Glycosides of Pyrido [2,3-c]-1,2,6-thiadiazine 2,2-Dioxides. Nucleosides & Nucleotides, 1990, 9, 69-79.	0.5	3
286	Synthesis of a Valuable Precursor for the Preparation of Novel Quinolone Glycosides. Synlett, 1990, 1990, 753-754.	1.0	3
287	Comparative Molecular Field Analysis (CoMFA) on [6] + [6] Fused Pyrazines with Nematocide Properties. QSAR and Combinatorial Science, 1997, 16, 372-376.	1.4	3
288	Enzymatic alcoholysis of SO2-uracil analog diacyclonucleosides. Long-distance effect of the substituents on the regioselectivity. Journal of Molecular Catalysis B: Enzymatic, 1998, 4, 295-302.	1.8	3

#	Article	IF	Citations
289	Reductive Cleavage of Potential Cholinomimetics Thiadiazolidinones: A New Family of Spiro Compounds. European Journal of Organic Chemistry, 2000, 2000, 675-680.	1.2	3
290	P4-428 TDZDS: GSK3Î² inhibitors as therapeutic agents for Alzheimer's disease and other tauopathies. Neurobiology of Aging, 2004, 25, S596.	1.5	3
291	Molecular mechanics description of cytosine energy and geometry using preliminary ab initio results. Computational and Theoretical Chemistry, 2005, 729, 59-64.	1.5	3
292	Enantioselective LC/MS method for the determination of an antimalarial agent Fenozan B07 in dog plasma. Chirality, 2006, 18, 297-305.	1.3	3
293	QSAR Modelling for Drug Discovery: Predicting the Activity of LRRK2 Inhibitors for Parkinsonâ€™s Disease Using Cheminformatics Approaches. Advances in Intelligent Systems and Computing, 2019, , 63-70.	0.5	3
294	Chapter 9. Heterocycles Containing Nitrogen and Sulfur as Potent Biologically Active Scaffolds. RSC Drug Discovery Series, 2015, , 231-261.	0.2	3
295	Glycogen Synthase Kinase-3Î² Expression and Phosphorylation in Peripheral Blood Mononuclear Cells of Patients with Amyotrophic Lateral Sclerosis. British Journal of Medicine and Medical Research, 2014, 4, 263-271.	0.2	3
296	TDP-43 Pathology and Prionic Behavior in Human Cellular Models of Alzheimerâ€™s Disease Patients. Biomedicines, 2022, 10, 385.	1.4	3
297	The molecular structure of 3(5)-methyl-4,5(3)-trimethylenepyrazole hydrochloride and its13C and15N NMR spectroscopy. Journal of Crystallographic and Spectroscopic Research, 1993, 23, 961-965.	0.3	2
298	Molecular modeling of (E)-1-alkyl-4(3)-[2-(1H-azolyl)vinyl]-pyridinium salts and evaluation of their behavior towards choline acetyltransferase. Bioorganic and Medicinal Chemistry, 1997, 5, 949-954.	1.4	2
299	Towards lipophilic derivatives of Sâ€adenosylâ€Lâ€methionine. Journal of Heterocyclic Chemistry, 1998, 35, 727-730.	1.4	2
300	Studies on the reactivity of some Nâ€arylâ€•and Nâ€heteroarylâ€N'â€alkylthioureas towards electrophilic reagents. Synthesis of new Nâ€pyridylthioureas and thiazolines marÃa. Journal of Heterocyclic Chemistry, 2001, 38, 435-441.	1.4	2
301	TDZD's: Selective and ATP Noncompetitive Glycogen Synthase Kinase 3 Inhibitors. , 0, , 257-280.		2
302	Electron Correlated Ab Initio Study of Amino Group Flexibility for Improvement of Molecular Mechanics Simulations on Nucleic Acid Conformations and Interactions. Journal of Biological Physics, 2007, 33, 499-514.	0.7	2
303	Therapeutic approaches for the future treatment of Fragile X. Current Opinion in Behavioral Sciences, 2015, 4, 6-21.	2.0	2
304	Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 511-523.	2.5	2
305	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Proteinâ€Templated Synthesis. Angewandte Chemie, 2021, 133, 19493-19503.	1.6	2
306	Synthesis of New N-(4-Pyridyl)-1-aminopyrazoles and Their Muscarinic and Adrenergic Properties. Archiv Der Pharmazie, 2000, 333, 118-122.	2.1	2

#	Article	IF	Citations
307	Medicinal Chemistry Strategies to Discover New Leishmanicidal Drugs. RSC Drug Discovery Series, 2017, , 153-178.	0.2	2
308	The Crystal Structures of Glycogen Synthase Kinase 3. , 0, , 61-82.		1
309	Chapter 9. Tau Protein Kinases Inhibitors: From the Bench to the Clinical Trials. RSC Drug Discovery Series, 2010, , 173-194.	0.2	1
310	Synthesis and Biological Evaluation of Tacrine-Thiadiazolidinone Hybrids as Dual Acetylcholinesterase Inhibitors.. ChemInform, 2005, 36, no.	0.1	0
311	Cyclic Nucleotide Phosphodiesterases and Their Role in Immunomodulatory Responses: Advances in the Development of Specific Phosphodiesterase Inhibitors. ChemInform, 2005, 36, no.	0.1	0
312	GSK-3, a Key Player in Alzheimer's Disease. , 0, , 105-124.		0
313	Protein Kinase Assays for Drug Discovery. , 0, , 189-201.		0
314	Preface [Hot topic: Neuropathic Pain: Some Clues for the Future (Executive Editor: Ana Martinez)]. Mini-Reviews in Medicinal Chemistry, 2003, 3, 718-718.	1.1	0
315	An aminophenothiazine inhibitor of the NCS-1/Ric8a complex regulates synaptic function in fragile X syndrome. Acta Crystallographica Section A: Foundations and Advances, 2018, 74, e38-e39.	0.0	0
316	Protein Kinase Inhibitors for the Treatment of Multiple Sclerosis. RSC Drug Discovery Series, 2019, , 170-196.	0.2	0